The Science of
Self-Optimization

FDA Peptide Reclassification 2026: What's Changing, What's Not, and What It Means for Your Protocol

RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.

The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.